Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0H2RJ
|
||||
Former ID |
DNCL001903
|
||||
Drug Name |
Clazosentan
|
||||
Drug Type |
Small molecular drug
|
||||
Indication | Vasospasm following subarachnoid hemorrhage [ICD9: 430, 728.85, 852.0, 852.1; ICD10:I60, P10.3, R25.2, S06.6] | Discontinued in Phase 3 | [547565] | ||
Company |
Actelion Pharmaceuticals
|
||||
Structure |
Download2D MOL |
||||
Formula |
C25H23N9O6S
|
||||
Canonical SMILES |
CC1=CN=C(C=C1)S(=O)(=O)NC2=C(C(=NC(=N2)C3=CC(=NC=C3)C4=<br />NNN=N4)OCCO)OC5=CC=CC=C5OC
|
||||
InChI |
1S/C25H23N9O6S/c1-15-7-8-20(27-14-15)41(36,37)32-24-21(40-19-6-4-3-5-18(19)38-2)25(39-12-11-35)29-22(28-24)16-9-10-26-17(13-16)23-30-33-34-31-23/h3-10,13-14,35H,11-12H2,1-2H3,(H,28,29,32)(H,30,31,33,34)
|
||||
InChIKey |
LFWCJABOXHSRGC-UHFFFAOYSA-N
|
||||
PubChem Compound ID | |||||
PubChem Substance ID | |||||
Target and Pathway | |||||
Target(s) | Endothelin-1 receptor | Target Info | Antagonist | [528988] | |
NetPath Pathway | IL4 Signaling Pathway | ||||
PANTHER Pathway | Endothelin signaling pathway | ||||
Pathway Interaction Database | Endothelins | ||||
EGFR-dependent Endothelin signaling events | |||||
References | |||||
Ref 528988 | Effects of the selective endothelin A (ET(A)) receptor antagonist Clazosentan on cerebral perfusion and cerebral oxygenation following severe subarachnoid hemorrhage - preliminary results from a randomized clinical series. Acta Neurochir (Wien). 2007;149(9):911-8; discussion 918. Epub 2007 Aug 13. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.